Los Angeles Capital Management’s ADMA Biologics ADMA Stock Holding History

Los Angeles Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$314K	Sell	37,492 -235,284	-86%	-$2.14M	﹤0.01%	1046
2026 Q1	$2.46M	Buy	272,776 +254,467	+1,390%	+$4.02M	0.01%	458
2025 Q4	$280K	Hold	18,309	–	–	﹤0.01%	1124
2025 Q3	$268K	Sell	18,309 -53,065	-74%	-$910K	﹤0.01%	1168
2025 Q2	$1.3M	Sell	71,374 -51,670	-42%	-$1.05M	﹤0.01%	579
2025 Q1	$2.44M	Buy	123,044 +39,804	+48%	+$688K	0.01%	371
2024 Q4	$1.43M	Sell	83,240 -65,250	-44%	-$1.23M	0.01%	524
2024 Q3	$2.97M	Buy	148,490 +67,740	+84%	+$1.05M	0.01%	387
2024 Q2	$903K	Buy	+80,750	New	+$677K	﹤0.01%	685
2021 Q3	–	Sell	-37,165	Closed	-$59K	–	1462
2021 Q2	$59K	Sell	37,165 -2,100	-5%	-$3.69K	﹤0.01%	1516
2021 Q1	$69K	Sell	39,265 -34,100	-46%	-$78K	﹤0.01%	1570
2020 Q4	$143K	Buy	73,365 +50	+0.1%	+$105	﹤0.01%	1489
2020 Q3	$175K	Sell	73,315 -9,830	-12%	-$27K	﹤0.01%	1403
2020 Q2	$244K	Buy	83,145 +57,010	+218%	+$164K	﹤0.01%	1344
2020 Q1	$75K	Buy	+26,135	New	+$90.3K	﹤0.01%	1310

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Los Angeles Capital Management's ADMA Position: Q2 2026 in Review

Los Angeles Capital Management reduced its ADMA Biologics (ADMA) stake by 86% in Q2 2026, selling an estimated $2.14M and leaving 37,492 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

Los Angeles Capital Management first reported a position in ADMA in Q1 2020 and has held it in 15 quarters since. The position peaked at $2.97M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Los Angeles Capital Management held 37,492 shares of ADMA Biologics worth $314K as of Q2 2026.
Los Angeles Capital Management sold 235,284 ADMA Biologics shares in Q2 2026, an estimated $2.14M.
ADMA Biologics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1046 holding.
Los Angeles Capital Management first reported a position in ADMA Biologics in Q1 2020 and has held it in 15 quarters since.
Los Angeles Capital Management's ADMA Biologics position peaked at $2.97M in Q3 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.